| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1005455311 |
| P356 | DOI | 10.1038/SJ.GT.3301033 |
| P698 | PubMed publication ID | 10637445 |
| P5875 | ResearchGate publication ID | 12677913 |
| P2093 | author name string | Davidson BL | |
| Bohn MC | |||
| Connor B | |||
| Kozlowski DA | |||
| Schallert T | |||
| Tillerson JL | |||
| P2860 | cites work | Functional recovery in parkinsonian monkeys treated with GDNF | Q24312738 |
| GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons | Q24336322 | ||
| Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum | Q24557423 | ||
| Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo | Q28306009 | ||
| Aging and the basal ganglia | Q32053935 | ||
| Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats | Q33745707 | ||
| Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion | Q33939425 | ||
| Age-related decline in the dopaminergic nigrostriatal system: the oxidative hypothesis and protective strategies | Q35753858 | ||
| A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal | Q35915922 | ||
| Recombinational construction in Escherichia coli of infectious adenoviral genomes | Q35997183 | ||
| An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene | Q36163092 | ||
| Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. | Q36561684 | ||
| Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector | Q37251114 | ||
| Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. | Q37334431 | ||
| A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase | Q37551841 | ||
| Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors | Q37652057 | ||
| Amphetamine regulates gene expression in rat striatum via transcription factor CREB. | Q38304588 | ||
| Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted | Q39642143 | ||
| Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. | Q39878778 | ||
| Neurotrophic growth factors and neurodegenerative diseases: therapeutic potential of the neurotrophins and ciliary neurotrophic factor | Q40580738 | ||
| Cellular and molecular mechanisms of impaired dopaminergic function during aging | Q40660411 | ||
| Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression | Q40972848 | ||
| Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. | Q40983409 | ||
| GDNF administration induces recovery of the nigrostriatal dopaminergic system both in young and aged parkinsonian mice | Q41019022 | ||
| Expression of GDNF family receptor components during development: implications in the mechanisms of interaction. | Q41036193 | ||
| Localization of glial cell line-derived neurotrophic factor receptor alpha and c-ret mRNA in rat central nervous system | Q41053776 | ||
| Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. | Q41063070 | ||
| Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): preclinical development and application to the treatment of Parkinson's disease | Q41107046 | ||
| Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates multiple mechanisms of trophic actions in the adult rat CNS. | Q41110376 | ||
| Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery | Q41114195 | ||
| Glial cell line-derived neurotrophic factor induces the dopaminergic and cholinergic phenotype and increases locomotor activity in aged Fischer 344 rats | Q41119830 | ||
| Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy | Q41122354 | ||
| Dopaminergic neurons protected from degeneration by GDNF gene therapy | Q41128316 | ||
| Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease | Q41137349 | ||
| Intranigral or intrastriatal injections of GDNF: effects on monoamine levels and behavior in rats | Q41144604 | ||
| GDNF: a cytokine at the interface of TGF-betas and neurotrophins | Q41150084 | ||
| Alleviation of behavioral deficits in aged rodents following implantation of encapsulated GDNF-producing fibroblasts | Q41158860 | ||
| Glial cell line-derived neurotrophic factor reverses motor impairment in 16-17 month old rats. | Q41190734 | ||
| Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis | Q41226051 | ||
| The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments | Q41277031 | ||
| Characterization of an adenovirus gene transfer vector containing an E4 deletion | Q41286200 | ||
| Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. | Q41345669 | ||
| Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms | Q41365447 | ||
| GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo | Q41368638 | ||
| Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain | Q41379201 | ||
| Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo | Q41428400 | ||
| Recombinant adenovirus: a gene transfer vector for study and treatment of CNS diseases | Q41450717 | ||
| Adenovirus-mediated gene transfer to the central nervous system for Parkinson's disease | Q41450723 | ||
| Rescuing neurons from trans-synaptic degeneration after brain damage: helpful, harmful, or neutral in recovery of function? | Q42001638 | ||
| Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain | Q42280576 | ||
| Dopamine and glutamate agonists stimulate neuron-specific expression of Fos-like protein in the striatum | Q42453575 | ||
| D1-dopamine receptor agonists selectively activate striatal c-fos independent of rotational behaviour | Q43416396 | ||
| Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. | Q43535009 | ||
| D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons | Q44243782 | ||
| Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector | Q45769447 | ||
| Inflammatory responses and their impact on beta-galactosidase transgene expression following adenovirus vector delivery to the primate caudate nucleus | Q45861874 | ||
| An adenovirus vector for gene transfer into neurons and glia in the brain | Q45874317 | ||
| Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors | Q45875094 | ||
| Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors | Q45884182 | ||
| A Clinically Relevant Unilateral Rat Model of Parkinsonian Akinesia. | Q46030015 | ||
| Dopaminergic Changes in the Basal Ganglia A Generalized Phenomenon of Aging in Mammals | Q46322618 | ||
| Use-dependent growth of pyramidal neurons after neocortical damage. | Q48144187 | ||
| Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. | Q48170542 | ||
| Adenovirus-mediated transgene expression in nonhuman primate brain | Q48201318 | ||
| A model system for in vivo gene transfer into the central nervous system using an adenoviral vector | Q48325479 | ||
| Extensive beta-glucuronidase activity in murine central nervous system after adenovirus-mediated gene transfer to brain | Q48342498 | ||
| Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. | Q48408339 | ||
| D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease | Q48427737 | ||
| Overgrowth and pruning of dendrites in adult rats recovering from neocortical damage | Q48479638 | ||
| Dopaminergic transplants normalize amphetamine- and apomorphine-induced Fos expression in the 6-hydroxydopamine-lesioned striatum | Q48594848 | ||
| Use-dependent exaggeration of neuronal injury after unilateral sensorimotor cortex lesions. | Q48957307 | ||
| Intrastriatal grafts derived from fetal striatal primordia: II. Reconstitution of cholinergic and dopaminergic systems | Q49014717 | ||
| Time course of striatal changes induced by 6-hydroxydopamine lesion of the nigrostriatal pathway, as studied by combined evaluation of rotational behaviour and striatal Fos expression. | Q49137803 | ||
| Transfer of a foreign gene into the brain using adenovirus vectors | Q64377820 | ||
| Adenovirus gene transfer causes inflammation in the brain | Q64383186 | ||
| Sex differences in drug-induced rotation in two strains of rats | Q70937344 | ||
| Differential effects of the intraventricular administration of 6-hydroxydopamine on the induction of type II beta-tubulin and tyrosine hydroxylase mRNA in the locus coeruleus of the aging Fischer 344 rat | Q71489320 | ||
| Characteristics of dopaminergic neurons in the aged male rat | Q71516358 | ||
| The role of neuronal growth factors in neurodegenerative disorders of the human brain | Q74697359 | ||
| Estimation of nuclear population from microtome sections | Q82126847 | ||
| P433 | issue | 12 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| substantia nigra | Q753278 | ||
| striatum | Q1319792 | ||
| cell line | Q21014462 | ||
| P304 | page(s) | 1936-1951 | |
| P577 | publication date | 1999-12-01 | |
| P1433 | published in | Gene Therapy | Q15763095 |
| P1476 | title | Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. | |
| P478 | volume | 6 |
| Q28115736 | A specific survival response in dopamine neurons at most risk in Parkinson's disease |
| Q35216667 | Adeno-associated viral vectors for Parkinson's disease |
| Q34434662 | Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides neuroprotection in the aged parkinsonian rat. |
| Q41874717 | An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons |
| Q43068412 | Assessment of sensorimotor function in mouse models of Parkinson's disease |
| Q39440585 | Behavioral and structural effects of unilateral intrastriatal injections of botulinum neurotoxin a in the rat model of Parkinson's disease |
| Q37629981 | Behavioral outcome measures for the assessment of sensorimotor function in animal models of movement disorders |
| Q90196675 | Beta Frequency Oscillations in the Subthalamic Nucleus Are Not Sufficient for the Development of Symptoms of Parkinsonian Bradykinesia/Akinesia in Rats |
| Q73503153 | CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury |
| Q44297524 | Cell transplantation and gene therapy in Parkinson's disease |
| Q39524681 | Combining glial cell line-derived neurotrophic factor gene delivery (AdGDNF) with L-arginine decreases contusion size but not behavioral deficits after traumatic brain injury |
| Q40737427 | Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease |
| Q40599126 | Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease |
| Q34684014 | Differentiation and transcription factor gene therapy in experimental parkinson's disease: sonic hedgehog and Gli-1, but not Nurr-1, protect nigrostriatal cell bodies from 6-OHDA-induced neurodegeneration. |
| Q40210465 | Does neuronal expression of GDNF effectively protect dopaminergic neurons in a rat model of Parkinson's disease? |
| Q48492782 | Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease |
| Q43638930 | Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. |
| Q37696495 | Future of cell and gene therapies for Parkinson's disease |
| Q37203371 | GDNF therapy for Parkinson's disease |
| Q36150495 | Gene therapy for Parkinson's disease using recombinant adeno-associated viral vectors |
| Q37742852 | Glial Cell Line-Derived Neurotrophic Factor Gene Delivery in Parkinson's Disease: A Delicate Balance between Neuroprotection, Trophic Effects, and Unwanted Compensatory Mechanisms. |
| Q34026231 | Glial cell line-derived neurotrophic factor (GDNF) as a defensive molecule for neurodegenerative disease: a tribute to the studies of antonia vernadakis on neuronal-glial interactions |
| Q33787660 | Glial cell line-derived neurotrophic factor gene therapy ameliorates chronic hyperprolactinemia in senile rats |
| Q27002651 | Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain |
| Q40651049 | Intraputamenal infusion of GDNF in aged rhesus monkeys: Distribution and dopaminergic effects |
| Q31038741 | Localized striatal delivery of GDNF as a treatment for Parkinson disease |
| Q40874496 | Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. |
| Q47730351 | Methylphenidate and environmental enrichment ameliorate the deleterious effects of prenatal stress on attention functioning |
| Q34287016 | Nerve growth factor: from animal models of cholinergic neuronal degeneration to gene therapy in Alzheimer's disease |
| Q34997802 | Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF. |
| Q37796025 | Neurotrophic factor therapy for Parkinson’s disease |
| Q33985663 | Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders |
| Q55409849 | Pre-α-pro-GDNF and Pre-β-pro-GDNF Isoforms Are Neuroprotective in the 6-hydroxydopamine Rat Model of Parkinson's Disease. |
| Q40843723 | Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor |
| Q34515354 | Prospects for the treatment of Parkinson's disease using neurotrophic factors |
| Q34095954 | Protective effect of alpha-synuclein knockdown on methamphetamine-induced neurotoxicity in dopaminergic neurons |
| Q36289043 | RET signaling does not modulate MPTP toxicity but is required for regeneration of dopaminergic axon terminals. |
| Q34361466 | Regulatable and cell-type specific transgene expression in glial cells: prospects for gene therapy for neurological disorders |
| Q39792829 | Reversal of dopaminergic degeneration in a parkinsonian rat following micrografting of human bone marrow-derived neural progenitors |
| Q24794457 | Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease |
| Q27316252 | The transfection of BDNF to dopamine neurons potentiates the effect of dopamine D3 receptor agonist recovering the striatal innervation, dendritic spines and motor behavior in an aged rat model of Parkinson's disease |
| Q35112002 | Therapeutic Gene Transfer to the Nervous System Using Viral Vectors |
| Q34105795 | Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model |
| Q64764679 | Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease |
| Q56947120 | Viral vector-mediated gene therapy for Parkinson's disease |
| Q33894621 | Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS |
Search more.